Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)
NCT05359120 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2022-09-19
Summary
This study aims to describe the different treatment time, treatment mode and clinical outcomes of pyrotinib maleate tablets combined with capecitabine in the treatment of patients with HER-2 positive advanced breast cancer with brain metastases.
Conditions
Sponsors & Collaborators
-
Henan Cancer Hospital
lead OTHER_GOV
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-30
- Primary Completion
- 2024-05-31
- Completion
- 2024-05-31
Countries
- China
Study Locations
More Related Trials
-
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
NCT07019337 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer
NCT04899128 ·Status: UNKNOWN
-
A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer
NCT04767828 ·Status: UNKNOWN ·Phase: PHASE4
-
Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer
NCT03923166 ·Status: UNKNOWN ·Phase: PHASE2
-
Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases
NCT04582968 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
NCT04609540 ·Status: UNKNOWN
-
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
NCT02973737 ·Status: UNKNOWN ·Phase: PHASE3
-
Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
NCT04001621 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
NCT06475443 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
NCT04246502 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
NCT02422199 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
NCT05861271 ·Status: RECRUITING ·Phase: PHASE2
-
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
NCT04850625 ·Status: COMPLETED
-
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
NCT03910712 ·Status: UNKNOWN ·Phase: PHASE2
-
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
NCT03086785 ·Status: UNKNOWN ·Phase: PHASE2
-
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
NCT04639271 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
NCT05560308 ·Status: UNKNOWN ·Phase: NA
-
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
NCT05346861 ·Status: UNKNOWN ·Phase: PHASE3
-
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
NCT03775928 ·Status: UNKNOWN ·Phase: PHASE2
-
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
NCT03080805 ·Status: UNKNOWN ·Phase: PHASE3
-
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
NCT04736589 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer
NCT01653561 ·Status: COMPLETED ·Phase: PHASE2
-
Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer
NCT03204734 ·Status: UNKNOWN ·Phase: PHASE2
-
A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer
NCT06339281 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients
NCT04517305 ·Status: COMPLETED